{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:01:35Z","timestamp":1791597695287,"version":"4.3.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,6]]},"DOI":"10.7759\/cureus.13173","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T04:28:32Z","timestamp":1612758512000},"source":"Crossref","is-referenced-by-count":15,"title":["Opioid Use Disorder: Treatments and Barriers"],"prefix":"10.7759","author":[{"given":"Karan","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Bunachita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ank A","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Lyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urvish K","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Opioid data analysis and resources. (2021). Accessed. January 26, 2021: https:\/\/www.cdc.gov\/drugoverdose\/data\/analysis.html."},{"key":"ref2","article-title":"Vital signs: overdoses of prescription opioid pain relievers \u2014 United States, 1999-2008","volume":"60","author":"Paulozzi LJ","year":"2011","unstructured":"Paulozzi LJ, Jones CM, Mack KA, Rudd RA. Vital signs: overdoses of prescription opioid pain relievers \u2014 United States, 1999-2008. MMWR Morb Mortal Wkly Rep. 2011, 60:1487-1492.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6533a2","article-title":"Fentanyl law enforcement submissions and increases in synthetic opioid-involved overdose deaths - 27 states, 2013-2014","volume":"65","author":"Gladden RM","year":"2016","unstructured":"Gladden RM, Martinez P, Seth P. Fentanyl law enforcement submissions and increases in synthetic opioid-involved overdose deaths - 27 states, 2013-2014. MMWR Morb Mortal Wkly Rep. 2016, 65:837-843. 10.15585\/mmwr.mm6533a2","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref4","article-title":"Increases in heroin overdose deaths \u2014 28 states, 2010 to 2012","volume":"63","author":"Rudd RA","year":"2014","unstructured":"Rudd RA, Paulozzi LJ, Bauer MJ, et al.. Increases in heroin overdose deaths \u2014 28 states, 2010 to 2012. MMWR Morb Mortal Wkly Rep. 2014, 63:849-854.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref5","unstructured":"Opioid crisis statistics. (2020). Accessed. January 26, 2021: https:\/\/www.hhs.gov\/opioids\/about-the-epidemic\/opioid-crisis-statistics\/index.html."},{"key":"ref6","unstructured":"CDC. drug overdose deaths up 4.6% in 2019. (2020). Accessed: January 26, 2021: https:\/\/www.aha.org\/news\/headline\/2020-07-16-cdc-drug-overdose-deaths-46-2019."},{"key":"ref7","article-title":"Comparison of healthcare delivery systems in low- and high-income communities","volume":"7","author":"Nguyen CA","year":"2019","unstructured":"Nguyen CA, Chernew ME, Ostrer I, Beaulieu ND. Comparison of healthcare delivery systems in low- and high-income communities. Am J Accountable Care. 2019, 7:11-18.","journal-title":"Am J Accountable Care"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.7621","article-title":"Prevention of prescription opioid misuse and projected overdose deaths in the United States","volume":"2","author":"Chen Q","year":"2019","unstructured":"Chen Q, Larochelle MR, Weaver DT, et al.. Prevention of prescription opioid misuse and projected overdose deaths in the United States. JAMA Netw Open. 2019, 2:e187621. 10.1001\/jamanetworkopen.2018.7621","journal-title":"JAMA Netw Open"},{"key":"ref9","unstructured":"Overdose death urbanicity graphs. (2020). Accessed. January 26, 2021: https:\/\/www.cdc.gov\/drugoverdose\/data\/prescribing\/overdose-death-urbanicity.html."},{"key":"ref10","article-title":"Availability and utilization of opioids for pain management: global issues","volume":"14","author":"Manjiani D","year":"2014","unstructured":"Manjiani D, Paul DB, Kunnumpurath S, Kaye AD, Vadivelu N. Availability and utilization of opioids for pain management: global issues. Ochsner J. 2014, 14:208-215.","journal-title":"Ochsner J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman SE","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, et al.. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020, 3:e1920622. 10.1001\/jamanetworkopen.2019.20622","journal-title":"JAMA Netw Open"},{"key":"ref12","article-title":"Buprenorphine","author":"Kumar R","year":"2020","unstructured":"Kumar R, Viswanath O, Saadabadi A. Buprenorphine. StatPearls [Internet], Treasure Island, FL; 2020."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1989.66","article-title":"Sublingual versus subcutaneous buprenorphine in opiate abusers","volume":"45","author":"Jasinski DR","year":"1989","unstructured":"Jasinski DR, Fudala PJ, Johnson RE. Sublingual versus subcutaneous buprenorphine in opiate abusers. Clin Pharmacol Ther. 1989, 45:513-519. 10.1038\/clpt.1989.66","journal-title":"Clin Pharmacol Ther"},{"key":"ref14","unstructured":"NIH. How much does opioid treatment cost?. (2018). Accessed. January 26, 2021: https:\/\/www.drugabuse.gov\/publications\/research-reports\/medications-to-treat-opioid-addiction\/how-much-does-opioid-tr...."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00637-z","article-title":"Buprenorphine treatment for opioid use disorder: an overview","volume":"33","author":"Shulman M","year":"2019","unstructured":"Shulman M, Wai JM, Nunes EV. Buprenorphine treatment for opioid use disorder: an overview. CNS Drugs. 2019, 33:567-580. 10.1007\/s40263-019-00637-z","journal-title":"CNS Drugs"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000457","article-title":"Buprenorphine pharmacology review: update on transmucosal and long-acting formulations","volume":"13","author":"Coe MA","year":"2019","unstructured":"Coe MA, Lofwall MR, Walsh SL. Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med. 2019, 13:93-103. 10.1097\/ADM.0000000000000457","journal-title":"J Addict Med"},{"key":"ref17","article-title":"Buprenorphine maintenance vs. placebo for opioid dependence","author":"Raleigh MF","year":"2017","unstructured":"Raleigh MF. Buprenorphine maintenance vs. placebo for opioid dependence. Am Fam Physician. 2017, 95:[Epub]. Accessed: February 3, 2021: https:\/\/www.aafp.org\/afp\/2017\/0301\/od1.html."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.15629","article-title":"Statins for prevention of cardiovascular disease in adults. Evidence report and systematic review for the US Preventive Services Task Force","volume":"316","author":"Chou R","year":"2016","unstructured":"Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults. Evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016, 316:2008-2024. 10.1001\/jama.2015.15629","journal-title":"JAMA"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.172","article-title":"Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study","volume":"22","author":"Bruera E","year":"2004","unstructured":"Bruera E, Palmer JL, Bosnjak S, et al.. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol. 2004, 22:185-192. 10.1200\/JCO.2004.03.172","journal-title":"J Clin Oncol"},{"key":"ref20","unstructured":"Methadone oral concentrate. (2016). Accessed. January 26, 2021: https:\/\/www.rxlist.com\/methadone-oral-concentrate-drug.htm."},{"key":"ref21","article-title":"Methadone","volume":"109","author":"Sim SK","year":"1973","unstructured":"Sim SK. Methadone. Can Med Assoc J. 1973, 109:615-619.","journal-title":"Can Med Assoc J"},{"key":"ref22","unstructured":"Methadone. (2020). Accessed. January 26, 2021: https:\/\/medlineplus.gov\/druginfo\/meds\/a682134.html."},{"key":"ref23","unstructured":"PCPs don\u2019t back \u201cgold standard\u201d treatment for opioid addiction. (2020). Accessed. January 26, 2021: https:\/\/www.medscape.com\/viewarticle\/929080."},{"key":"ref24","unstructured":"What is cognitive behavioral therapy?. (2017). Accessed. January 26, 2021: https:\/\/www.apa.org\/ptsd-guideline\/patients-and-families\/cognitive-behavioral."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2010.04.012","article-title":"Cognitive behavioral therapy for substance use disorders","volume":"33","author":"McHugh RK","year":"2010","unstructured":"McHugh RK, Hearon BA, Otto MW. Cognitive behavioral therapy for substance use disorders. Psychiatr Clin North Am. 2010, 33:511-525. 10.1016\/j.psc.2010.04.012","journal-title":"Psychiatr Clin North Am"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2020.1780602","article-title":"Cognitive-behavioral therapy and buprenorphine for opioid use disorder: a systematic review and meta-analysis of randomized controlled trials","volume":"46","author":"Gregory VL","year":"2020","unstructured":"Gregory VL, Ellis RJB. Cognitive-behavioral therapy and buprenorphine for opioid use disorder: a systematic review and meta-analysis of randomized controlled trials. Am J Drug Alcohol Abuse. 2020, 46:520-530. 10.1080\/00952990.2020.1780602","journal-title":"Am J Drug Alcohol Abuse"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psychotherapy.2006.60.3.233","article-title":"Cognitive-behavioral therapy and psychodynamic psychotherapy: techniques, efficacy, and indications","volume":"60","author":"Leichsenring F","year":"2006","unstructured":"Leichsenring F, Hiller W, Weissberg M, Leibing E. Cognitive-behavioral therapy and psychodynamic psychotherapy: techniques, efficacy, and indications. Am J Psychother. 2006, 60:233-259. 10.1176\/appi.psychotherapy.2006.60.3.233","journal-title":"Am J Psychother"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127598","article-title":"Efficacy of cognitive behavioral therapy on opiate use and retention in methadone maintenance treatment in China: a randomised trial","volume":"10","author":"Pan S","year":"2015","unstructured":"Pan S, Jiang H, Du J, Chen H, Li Z, Ling W, Zhao M. Efficacy of cognitive behavioral therapy on opiate use and retention in methadone maintenance treatment in China: a randomised trial. PLoS One. 2015, 10:0127598. 10.1371\/journal.pone.0127598","journal-title":"PLoS One"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.10.015","article-title":"An evaluation of the feasibility, acceptability, and preliminary efficacy of cognitive-behavioral therapy for opioid use disorder and chronic pain","volume":"194","author":"Barry DT","year":"2019","unstructured":"Barry DT, Beitel M, Cutter CJ, et al.. An evaluation of the feasibility, acceptability, and preliminary efficacy of cognitive-behavioral therapy for opioid use disorder and chronic pain. Drug Alcohol Depend. 2019, 194:460-467. 10.1016\/j.drugalcdep.2018.10.015","journal-title":"Drug Alcohol Depend"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01581.x","article-title":"Contingency management for treatment of substance use disorders: a meta-analysis","volume":"101","author":"Prendergast M","year":"2006","unstructured":"Prendergast M, Podus D, Finney J, Greenwell L, Roll J. Contingency management for treatment of substance use disorders: a meta-analysis. Addiction. 2006, 101:1546-1560. 10.1111\/j.1360-0443.2006.01581.x","journal-title":"Addiction"},{"key":"ref31","unstructured":"NIH. Contingency management interventions\/motivational incentives (alcohol, stimulants, opioids, marijuana, nicotine). (2018). Accessed. January 26, 2021: https:\/\/www.drugabuse.gov\/publications\/principles-drug-addiction-treatment-research-based-guide-third-edition\/evidenc...."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s40614-019-00214-1","article-title":"Technology-based contingency management in the treatment of substance-use disorders","volume":"42","author":"Dallery J","year":"2019","unstructured":"Dallery J, Raiff BR, Grabinski MJ, Marsch LA. Technology-based contingency management in the treatment of substance-use disorders. Perspect Behav Sci. 2019, 42:445-464. 10.1007\/s40614-019-00214-1","journal-title":"Perspect Behav Sci"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1192\/pb.bp.110.031831","article-title":"Contingency management: what it is and why psychiatrists should want to use it","volume":"35","author":"Petry NM","year":"2011","unstructured":"Petry NM. Contingency management: what it is and why psychiatrists should want to use it. Psychiatrist. 2011, 35:161-163. 10.1192\/pb.bp.110.031831","journal-title":"Psychiatrist"},{"key":"ref34","unstructured":"Improving access to evidence-based medical treatment for opioid use disorder. strategies to address key barriers within the treatment system. (2020). https:\/\/nam.edu\/improving-access-to-evidence-based-medical-treatment-for-opioid-use-disorder-strategies-to-address-ke...."},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2013.02.018","article-title":"Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review","volume":"131","author":"Van Boekel LC","year":"2013","unstructured":"Van Boekel LC, Brouwers EPM, Van Weeghel J, Garretsen HFL. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend. 2013, 131:23-35. 10.1016\/j.drugalcdep.2013.02.018","journal-title":"Drug Alcohol Depend"},{"key":"ref36","article-title":"GPs\u2019 attitudes towards the treatment of drug misusers","volume":"50","author":"McGillion J","year":"2000","unstructured":"McGillion J, Wanigaratne S, Feinmann C, Godden T, Byrne A. GPs\u2019 attitudes towards the treatment of drug misusers. Br J Gen Pr. 2000, 50:385-386.","journal-title":"Br J Gen Pr"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2524.2006.00683.x","article-title":"Too frightened to care? Accounts by district nurses working with clients who misuse substances","volume":"15","author":"Peckover S","year":"2007","unstructured":"Peckover S, Chidlaw RG. Too frightened to care? Accounts by district nurses working with clients who misuse substances. Health Soc Care Community. 2007, 15:238-245. 10.1111\/j.1365-2524.2006.00683.x","journal-title":"Health Soc Care Community"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-8180(02)00359-8","article-title":"Attitudes of anesthesiologists about addiction and its treatment: a survey of Illinois and Wisconsin members of the American society of anesthesiologists","volume":"14","author":"May JA","year":"2002","unstructured":"May JA, Warltier DC, Pagel PS. Attitudes of anesthesiologists about addiction and its treatment: a survey of Illinois and Wisconsin members of the American society of anesthesiologists. J Clin Anesth. 2002, 14:284-289. 10.1016\/S0952-8180(02)00359-8","journal-title":"J Clin Anesth"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2702.2007.02266.x","article-title":"The determinants of nurses\u2019 therapeutic attitude to patients who use illicit drugs and implications for workforce development","volume":"17","author":"Ford R","year":"2008","unstructured":"Ford R, Bammer G, Becker N. The determinants of nurses\u2019 therapeutic attitude to patients who use illicit drugs and implications for workforce development. J Clin Nurs. 2008, 17:2452-2462. 10.1111\/j.1365-2702.2007.02266.x","journal-title":"J Clin Nurs"},{"key":"ref40","unstructured":"Statutes, regulations, and guidelines. (2020). Accessed. January 26, 2021: https:\/\/www.samhsa.gov\/medication-assisted-treatment\/statutes-regulations-guidelines."},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-05721-5","article-title":"Federal barriers to addressing the opioid epidemic","volume":"35","author":"Kleinman RA","year":"2020","unstructured":"Kleinman RA, Morris NP. Federal barriers to addressing the opioid epidemic. J Gen Intern Med. 2020, 35:1304-1306. 10.1007\/s11606-020-05721-5","journal-title":"J Gen Intern Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1186\/1940-0640-7-10","article-title":"Just call it \u201ctreatment\u201d","volume":"7","author":"Friedmann PD","year":"2012","unstructured":"Friedmann PD, Schwartz RP. Just call it \u201ctreatment\u201d. Addict Sci Clin Pract. 2012, 7:10. 10.1186\/1940-0640-7-10","journal-title":"Addict Sci Clin Pract"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.3505","article-title":"Making amends for the opioid epidemic","volume":"321","author":"Sharfstein JM","year":"2019","unstructured":"Sharfstein JM, Olsen Y. Making amends for the opioid epidemic. JAMA. 2019, 321:1446-1447. 10.1001\/jama.2019.3505","journal-title":"JAMA"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2017.12.022","article-title":"Policy pathways to address provider workforce barriers to buprenorphine treatment","volume":"54","author":"Haffajee RL","year":"2018","unstructured":"Haffajee RL, Bohnert ASB, Lagisetty PA. Policy pathways to address provider workforce barriers to buprenorphine treatment. Am J Prev Med. 2018, 54:230-242. 10.1016\/j.amepre.2017.12.022","journal-title":"Am J Prev Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2014.12143.x","article-title":"Preliminary survey of office-based opioid treatment practices and attitudes among psychiatrists never receiving buprenorphine training to those who received training during residency","volume":"23","author":"Suzuki J","year":"2014","unstructured":"Suzuki J, Connery HS, Ellison T V, Renner JA. Preliminary survey of office-based opioid treatment practices and attitudes among psychiatrists never receiving buprenorphine training to those who received training during residency. Am J Addict. 2014, 23:618-622. 10.1111\/j.1521-0391.2014.12143.x","journal-title":"Am J Addict"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/51800-opioid-use-disorder-treatments-and-barriers","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:33:40Z","timestamp":1707507220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/51800-opioid-use-disorder-treatments-and-barriers"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,6]]},"references-count":45,"URL":"https:\/\/doi.org\/10.7759\/cureus.13173","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,6]]}}}